HRP20140892T1 - Novi hidroksi-6-heteroarilfenantridini i njihova uporaba kao inhibitora za pde4 - Google Patents

Novi hidroksi-6-heteroarilfenantridini i njihova uporaba kao inhibitora za pde4 Download PDF

Info

Publication number
HRP20140892T1
HRP20140892T1 HRP20140892TT HRP20140892T HRP20140892T1 HR P20140892 T1 HRP20140892 T1 HR P20140892T1 HR P20140892T T HRP20140892T T HR P20140892TT HR P20140892 T HRP20140892 T HR P20140892T HR P20140892 T1 HRP20140892 T1 HR P20140892T1
Authority
HR
Croatia
Prior art keywords
salt
compound
formula
oxide
treatment
Prior art date
Application number
HRP20140892TT
Other languages
English (en)
Inventor
Ulrich Kautz
Beate Schmidt
Dieter Flockerzi
Armin Hatzelmann
Christof Zitt
Johannes Barsig
Degenhard Marx
Hans-Peter Kley
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of HRP20140892T1 publication Critical patent/HRP20140892T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Claims (25)

1. Spoj, naznačen time, da ima formulu I [image] u kojoj R1 je metoksi, R2 je metoksi, etoksi, difluorometoksi ili 2,2-difluoroetoksi, R3 je vodik, R31 je vodik, R4 je -O-R41, gdje R41 je vodik, Har je supstituiran s R6 i R7, i to je piridinil, gdje R6 je okso, i R7 je metil, ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili N-oksid od toga spoja.
2. Spoj formule I prema zahtjevu 1, naznačen time, da R1 je metoksi, R2 je metoksi, etoksi, difluorometoksi ili 2,2-difluoroetoksi, R3 je vodik, R31 je vodik, R4 je -O-R41, gdje R41 je vodik, R5 je vodik, Har je 1-metil-1H-piridin-2-on-5-il, ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili N-oksid od toga spoja.
3. Spoj formule I prema zahtjevu 1, naznačen time, da R1 je metoksi, R2 je etoksi, etoksi, difluorometoksi ili 2,2-difluoroetoksi, R3 je vodik, R31 je vodik, R4 je -O-R41, gdje R41 je vodik, R5 je vodik, Har je 1-metil-1H-piridin-2-on-5-il, ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili N-oksid od toga spoja.
4. Spoj formule I prema zahtjevu 1, naznačen time, da je to 5-((2R,4aR,10bR)-9-etoksi-2-hidroksi-8-metoksi-1,2,3,4,4a,10b-heksahidro-fenantridin-6-il)-1-metil-1H-piridin-2-on ili sol toga spoja.
5. Spoj formule I prema zahtjevu 1, naznačen time, da je to 5-((2R,4aR,10bR)-9-etoksi-2-hidroksi-8-metoksi-1,2,3,4,4a,10b-heksahidro-fenantridin-6-il)-1-metil-1H-piridin-2-on.
6. Spoj formule I prema bilo kojem od zahtjeva 1 do 3, naznačen time, da ima konfiguraciju prikazanu u formuli I*, u odnosu na pozicije 4a i 10b, [image] ili njegova sol, njegov N-oksid ili sol od N-oksida toga spoja.;
7. Spoj formule I prema bilo kojem od zahtjeva 1 do 3, naznačen time, da ima konfiguraciju prikazanu u formuli I*, u odnosu na pozicije 2, 4a i 10b, [image] ili njegova sol, njegov N-oksid ili sol od N-oksida toga spoja.
8. Spoj formule I ili njegova sol prema zahtjevu 4, naznačen time, da se upotrebljava u liječenju bolesti.
9. Spoj formule I prema zahtjevu 5, naznačen time, da se upotrebljava u liječenju bolesti.
10. Farmaceutski sastav, naznačen time, da obuhvaća jedan ili više spojeva formule I ili njegov enantiomer, njegovu sol, njegov N-oksid ili sol od enantiomera ili od N-oksida toga ili od tih spojeva prema bilo kojem od zahtjeva 1 do 3, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
11. Farmaceutski sastav, naznačen time, da obuhvaća spoj formule I ili njegovu sol prema zahtjevu 4, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
12. Farmaceutski sastav, naznačen time, da obuhvaća spoj formule I prema zahtjevu 5, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
13. Farmaceutski sastav, naznačen time, da obuhvaća jedan ili više spojeva formule I ili njegovu sol, njegov N-oksid ili sol od N-oksida toga ili tih spojeva prema bilo kojem od zahtjeva 6 ili 7, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
14. Uporaba spoja formule I ili njegovog enantiomera, njegove soli, njegovog N-oksida ili soli od enantiomera ili od N-oksida toga spoja prema bilo kojem od zahtjeva 1 do 3, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
15. Uporaba spoja formule I ili njegove soli prema zahtjevu 4, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
16. Uporaba spoja formule I ili njegove soli prema zahtjevu 4, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje mellitus dijabetesa.
17. Uporaba spoja formule I prema zahtjevu 5, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
18. Uporaba spoja formule I prema zahtjevu 5, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje mellitus dijabetesa.
19. Uporaba spoja formule I ili njegove soli, njegovog N-oksida ili soli od N-oksida toga spoja prema bilo kojem od zahtjeva 6 ili 7, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
20. Spoj formule I ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili od N-oksida toga spoja prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
21. Spoj formule I ili njegova sol prema zahtjevu 4, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
22. Spoj formule I ili njegova sol prema zahtjevu 4, naznačen time, da se upotrebljava za liječenje mellitus dijabetesa.
23. Spoj formule I prema zahtjevu 5, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
24. Spoj formule I prema zahtjevu 5, naznačen time, da se upotrebljava za liječenje mellitus dijabetesa.
25. Spoj formule I ili njegova sol ili njegov N-oksid, ili sol od N-oksida toga spoja prema bilo kojem od zahtjeva 6 ili 7, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
HRP20140892TT 2004-03-03 2014-09-17 Novi hidroksi-6-heteroarilfenantridini i njihova uporaba kao inhibitora za pde4 HRP20140892T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004973 2004-03-03
EP04106359 2004-12-07

Publications (1)

Publication Number Publication Date
HRP20140892T1 true HRP20140892T1 (hr) 2014-11-07

Family

ID=34921303

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20130828TT HRP20130828T1 (en) 2004-03-03 2013-09-05 Novel hydroxy-6-heroarylphenanthridines and their use as pde4 inhibitors
HRP20140892TT HRP20140892T1 (hr) 2004-03-03 2014-09-17 Novi hidroksi-6-heteroarilfenantridini i njihova uporaba kao inhibitora za pde4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20130828TT HRP20130828T1 (en) 2004-03-03 2013-09-05 Novel hydroxy-6-heroarylphenanthridines and their use as pde4 inhibitors

Country Status (29)

Country Link
US (8) US8003798B2 (hr)
EP (2) EP2589599B1 (hr)
JP (2) JP4801039B2 (hr)
KR (2) KR101152488B1 (hr)
CN (6) CN1922170A (hr)
AR (1) AR049319A1 (hr)
AU (1) AU2005219576B2 (hr)
BR (1) BRPI0508321B1 (hr)
CA (1) CA2557752C (hr)
CO (1) CO5700749A2 (hr)
CY (2) CY1114319T1 (hr)
DK (2) DK2589599T3 (hr)
EA (2) EA014155B1 (hr)
ES (2) ES2427256T3 (hr)
HK (4) HK1207635A1 (hr)
HR (2) HRP20130828T1 (hr)
IL (2) IL177073A (hr)
ME (1) ME01955B (hr)
MX (2) MXPA06009695A (hr)
NO (2) NO336538B1 (hr)
NZ (1) NZ549108A (hr)
PL (2) PL2589599T4 (hr)
PT (2) PT1723135E (hr)
RS (2) RS52916B (hr)
SG (1) SG182194A1 (hr)
SI (2) SI1723135T1 (hr)
TW (2) TWI404704B (hr)
WO (1) WO2005085225A1 (hr)
ZA (1) ZA200606176B (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281658T3 (es) 2002-08-29 2007-10-01 Nycomed Gmbh 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4.
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
ES2427256T3 (es) 2004-03-03 2013-10-30 Takeda Gmbh Nuevas hidroxi-6-heteroaril-fenantridinas y su uso como agentes inhibidores de la PDE4
CA2595252A1 (en) 2005-02-01 2006-08-10 Altana Pharma Ag Novel 6-pyridylphenanthridines
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.
EP1856092A1 (en) * 2005-03-02 2007-11-21 Nycomed GmbH 6-heteroaryl-1,2,3,4,4a,10b-hexahydro-phenanthridines as pde-4 inhibitors for the treatment of inflammatory disorders
MEP8509A (hr) * 2006-09-07 2011-12-20 Konbinovani tretman diabetis mellitus-a
CA2685858C (en) 2007-05-17 2015-11-24 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
WO2009025823A1 (en) * 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
AR074318A1 (es) 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
CA2936332A1 (en) * 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN103936661B (zh) * 2014-04-04 2016-08-24 常州大学 一种6-烷基菲啶衍生物的合成方法
EP3328381A1 (en) * 2015-07-29 2018-06-06 Takeda GmbH Pde4 inhibitor for the treatment of diabetic nephropathy
CA3034956A1 (en) * 2016-08-26 2018-03-01 Takeda Gmbh Treatment of nonalcoholic fatty liver disease
JP2020510071A (ja) 2017-03-16 2020-04-02 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特発性肺線維症の治療
WO2020113094A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
TWI753296B (zh) * 2019-08-30 2022-01-21 國立陽明交通大學 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法
TWI785816B (zh) * 2019-08-30 2022-12-01 國立陽明交通大學 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1995001338A1 (de) 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
EE03523B1 (et) 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
DE59708265D1 (de) * 1996-03-26 2002-10-24 Altana Pharma Ag Neue in 6-position substituierte phenanthridine
JPH1020274A (ja) * 1996-07-05 1998-01-23 Fujitsu Ltd 液晶表示駆動回路及び液晶表示装置
EE03829B1 (et) 1996-11-11 2002-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Bensonaftüridiinid, nende kasutamine bronhiaalravimi valmistamiseks ning neid sisaldav ravim
ATE248167T1 (de) 1997-03-07 2003-09-15 Altana Pharma Ag Tetrazole derivate
PT988302E (pt) 1997-06-03 2003-07-31 Altana Pharma Ag Benzonaftiridinas
HUP0002510A3 (en) 1997-07-25 2002-10-28 Altana Pharma Ag Tetrazole derivatives and pharmaceutical compositions containing them
DE69808099T2 (de) 1997-07-25 2003-05-15 Altana Pharma Ag Substituierte 6-alkylphenanthridine
US6121279A (en) 1997-07-25 2000-09-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-phenylphenanthridines
KR20010031783A (ko) * 1997-11-04 2001-04-16 데이비드 존 우드 Ｐｄｅ4 억제제 중 인다졸에 의한 카테콜의 생등입체성치환을 기재로 하는 치료상 활성인 화합물
SI1075477T1 (en) 1998-05-05 2003-08-31 Altana Pharma Ag Novel Benzonaphthyridine-N-oxides
ATE269331T1 (de) 1998-08-31 2004-07-15 Altana Pharma Ag Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
AU2107700A (en) 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
DK1147103T3 (da) * 1999-01-15 2005-08-29 Altana Pharma Ag Phenanthridin-N-oxider med PDE-IV-inhiberende aktivitet
US6476025B1 (en) 1999-01-15 2002-11-05 Altana Pharma Ag Phenylphennanthridines with PDE-IV inhibiting activity
US6479505B1 (en) * 1999-01-15 2002-11-12 Altana Pharma Ag 6-arylphenanthridines with PDE-IV inhibiting activity
AU2904300A (en) 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
CZ20021457A3 (cs) * 1999-10-25 2002-07-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopyranové sloučeniny
EP1250325B1 (en) 2000-01-11 2008-05-07 Nycomed GmbH Phenanthridine-n-oxides
ATE347557T1 (de) 2000-03-23 2006-12-15 Takeda Pharmaceutical Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
WO2002006238A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
EP1303506B1 (en) * 2000-07-14 2005-02-02 ALTANA Pharma AG 6-heteroarylphenanthridines
WO2002005616A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
EP1377574B1 (en) * 2001-02-21 2005-01-19 Byk Gulden Lomberg Chemische Fabrik GmbH 6-phenylbenzonaphthyridines
PL374014A1 (en) 2002-08-17 2005-09-19 Altana Pharma Ag Novel phenanthridines having pde 3/4 inhibiting properties
EP1581533A2 (en) 2002-08-17 2005-10-05 ALTANA Pharma AG Novel benzonaphthyridines
CA2495827C (en) * 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
ES2281658T3 (es) * 2002-08-29 2007-10-01 Nycomed Gmbh 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4.
RU2247262C2 (ru) 2003-05-19 2005-02-27 Федеральное государственное унитарное предприятие Российский Федеральный Ядерный Центр-Всероссийский Научно-исследовательский институт технической физики им. акад. Е.И. Забабахина (РФЯЦ- ВНИИТФ) Плунжерный насос сверхвысокого давления
EP1720835B1 (en) * 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
ES2427256T3 (es) 2004-03-03 2013-10-30 Takeda Gmbh Nuevas hidroxi-6-heteroaril-fenantridinas y su uso como agentes inhibidores de la PDE4
BRPI0508361A (pt) * 2004-03-09 2007-11-20 Altana Pharma Ag hidróxi-6-fenilfenantridinas substituìdas por isoamido
AU2005219581A1 (en) * 2004-03-10 2005-09-15 Nycomed Gmbh Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
BRPI0508481A (pt) 2004-03-10 2007-07-31 Altana Pharma Ag hidróxi-6-fenilenantridinas amido-substituìdas e seu uso como inibidores de pde4
EP1725533A1 (en) 2004-03-10 2006-11-29 Altana Pharma AG Novel thio containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.

Also Published As

Publication number Publication date
US8318944B2 (en) 2012-11-27
CN104803973A (zh) 2015-07-29
US20110257169A1 (en) 2011-10-20
IL221323A0 (en) 2012-09-24
EP2589599A1 (en) 2013-05-08
IL177073A0 (en) 2006-12-10
EP1723135A1 (en) 2006-11-22
AU2005219576B2 (en) 2011-06-30
ES2427256T3 (es) 2013-10-30
CN104817534A (zh) 2015-08-05
US9962377B2 (en) 2018-05-08
PL2589599T4 (pl) 2015-06-30
HRP20130828T1 (en) 2013-09-30
US20160279120A1 (en) 2016-09-29
BRPI0508321B1 (pt) 2018-02-06
ZA200606176B (en) 2008-03-26
HK1214812A1 (zh) 2016-08-05
BRPI0508321A (pt) 2007-07-24
CY1114319T1 (el) 2016-08-31
PT1723135E (pt) 2013-08-29
EA200601568A1 (ru) 2007-02-27
ME01955B (me) 2015-05-20
US8455653B2 (en) 2013-06-04
HK1208865A1 (en) 2016-03-18
CN1922170A (zh) 2007-02-28
EA014155B1 (ru) 2010-10-29
US9387205B2 (en) 2016-07-12
CA2557752C (en) 2012-10-02
EP1723135B1 (en) 2013-06-19
CN104761545A (zh) 2015-07-08
ES2505473T3 (es) 2014-10-10
PL2589599T3 (pl) 2015-04-30
SI1723135T1 (sl) 2013-10-30
US8324391B2 (en) 2012-12-04
TWI404704B (zh) 2013-08-11
US20140073636A1 (en) 2014-03-13
JP5193320B2 (ja) 2013-05-08
NO20064221L (no) 2006-09-19
US20110257221A1 (en) 2011-10-20
NZ549108A (en) 2010-06-25
PL1723135T3 (pl) 2013-11-29
HK1207635A1 (en) 2016-02-05
AR049319A1 (es) 2006-07-19
CN104803974A (zh) 2015-07-29
SG182194A1 (en) 2012-07-30
KR20120006080A (ko) 2012-01-17
KR101152439B1 (ko) 2012-07-06
MXPA06009695A (es) 2007-03-26
US20150119389A1 (en) 2015-04-30
US20080167301A1 (en) 2008-07-10
PT2589599E (pt) 2014-09-02
NO336538B1 (no) 2015-09-21
EP2589599B1 (en) 2014-06-25
DK1723135T5 (da) 2013-09-16
US9149479B2 (en) 2015-10-06
CO5700749A2 (es) 2006-11-30
EA201000494A1 (ru) 2010-08-30
NO20141541L (no) 2006-09-19
US8003798B2 (en) 2011-08-23
DK2589599T3 (da) 2014-10-06
US20150352096A1 (en) 2015-12-10
US8883818B2 (en) 2014-11-11
KR20060135837A (ko) 2006-12-29
JP2007526283A (ja) 2007-09-13
US20130045974A1 (en) 2013-02-21
CN102295634A (zh) 2011-12-28
IL177073A (en) 2013-04-30
WO2005085225A1 (en) 2005-09-15
DK1723135T3 (da) 2013-09-02
HK1208447A1 (en) 2016-03-04
AU2005219576A1 (en) 2005-09-15
RS53543B1 (en) 2015-02-27
JP2011074094A (ja) 2011-04-14
TWI372750B (en) 2012-09-21
CY1115536T1 (el) 2017-01-04
SI2589599T1 (sl) 2014-10-30
JP4801039B2 (ja) 2011-10-26
TW200540158A (en) 2005-12-16
MX341474B (es) 2016-08-19
TW201124381A (en) 2011-07-16
CA2557752A1 (en) 2005-09-15
RS52916B (en) 2014-02-28
NO338326B1 (no) 2016-08-08
KR101152488B1 (ko) 2012-07-02
EA017282B1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
HRP20140892T1 (hr) Novi hidroksi-6-heteroarilfenantridini i njihova uporaba kao inhibitora za pde4
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
CY1111651T1 (el) Παραγωγα 3-(ετεροαρυλ-oξυ)-2-αλκυλ-1-αζα- δικυκλοαλκυλιου ως συνδετες του αλφα.7-nachr για τη θεραπεια των ασθενειων του κνς
ME00155B (me) 5-SUPSTITUISANI HINOLIN I IZOHINOLIN DERIVATI, POSTUPAK NJIHOVE PROIZVODNJE l NJIHOVA UPOTREBA KAO ANTI-INFLAMATORNIH SREDSTAVA
MY147369A (en) (1-aza-bicyclo[3.3.1]non-4-yl)-5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disoders
HRP20070577T4 (hr) Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida
RS20090137A (en) Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
HRP20050641A2 (en) New carboxylic acids and the esters thereof, pharmaceutical compositions containing these compounds and processes for the preparation thereof
CN107428690A (zh) 可用于治疗癌症的突变idh1抑制剂
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
HRP20140501T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
MX2007003175A (es) Medicamentos que contienen compuestos de carbonilo y su uso.
CN106211770B (zh) 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮
HRP20050158A2 (en) Novel 2-arylthiazole compounds as pparalpha and ppargama agonists
WO2007083060A3 (fr) Derives de chalcone a activite antimitotique
MXPA04004373A (es) Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
WO2008074803A3 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
TW200730498A (en) Compounds
JP2016500653A5 (hr)